BSE · 526139
Transgene Biotek Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -650% net margin, versus -920% the period before.
Shareholding
As of 2026-06-30
- Promoter23.64%
- Public76.36%
13,817 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.46× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #335 of 541 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Ports & Special Economic Zone Ltd. | ₹4,07,340 Cr | 30.66 | 4.22 | 13.32% | 32.43% |
| Eternal Limited | ₹3,10,838 Cr | 715.78 | 9.97 | 1.18% | 0.64% |
| Vedanta Aluminium Metal Limited | ₹1,70,904 Cr | 14.23 | 436.95 | 49.39% | 21.35% |
| BSE Limited | ₹1,34,846 Cr | 47.62 | 20.21 | 37.42% | 52.03% |
| GAIL (India) Ltd. | ₹1,14,729 Cr | 11.62 | 1.29 | 8.51% | 6.67% |
| One 97 Communications Ltd. | ₹1,11,576 Cr | 137.47 | 6.96 | 4.55% | 7.25% |
| GMR Airports Limited | ₹1,02,908 Cr | 170.98 | 0 | -10.6% | 3.07% |
| Meesho Limited | ₹1,00,810 Cr | — | 22.95 | -28.13% | -8.68% |
| Mazagon Dock Shipbuilders Ltd. | ₹96,134 Cr | 33.64 | 9.9 | 26.48% | 21.45% |
| Multi Commodity Exchange of India Ltd. | ₹84,147 Cr | 54.58 | 29.54 | 46.75% | 58.61% |
| Transgene Biotek Ltd.(this company) | ₹22 Cr | — | 2.59 | -19.73% | -766.67% |
AI analysis
AI-generated · google/gemini-2.5-flashTransgene Biotek Ltd. (526139) has a market capitalization of Rs 22 Cr. The company reported a negative EPS of 0 and a negative return on equity (ROE) of -19.73%. Its debt-to-equity ratio stands at 1.38.
Positives
- +Promoter shareholding is not pledged, with promoter pledge at 0%.
Negatives
- −The company consistently reported negative net profits across all available quarterly data, such as -Rs 0.46 Cr for Mar 2026.
- −The profit margin is significantly negative at -825%.
- −Return on equity (ROE) is negative at -19.73%.
- −Return on capital employed (ROCE) is negative at -2.32%.
- −The debt-to-equity ratio is high at 1.38.
- −The company is under GSM (Graded Surveillance Measure) Stage 0.
Financial Performance
Transgene Biotek Ltd. reported quarterly revenues of Rs 0.05 Cr for the periods ending Jun 2025, Sept 2025, and Dec 2025. Net profit was negative across reported quarters, with -Rs 0.43 Cr in Jun 2025, -Rs 0.39 Cr in Sept 2025, and -Rs 0.37 Cr in Dec 2025.
Profitability & Returns
The company's profitability metrics are negative, with a profit margin of -825%. The return on equity (ROE) is -19.73%, and the return on capital employed (ROCE) is -2.32%. Earnings per share (EPS) is 0.
Balance Sheet
Transgene Biotek Ltd. has a book value of Rs 1.11 per share. The debt-to-equity ratio is 1.38, indicating that the company uses a significant amount of debt relative to its equity.
Ownership & Pledges
The public shareholding is 76.3627%. There are no pledged shares by the promoters.
Regulatory & Surveillance
The company is currently under GSM (Graded Surveillance Measure) Stage 0.
Data as of — price: 2026-09-11 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.